PTC Therapeutics | PTCT - Gross Profit On Sales


PTC Therapeutics reported $232.94M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Cytokinetics USD 23.03M 3.84M Jun/2026
Daiichi Sankyo JPY 287.15B 152.68B Mar/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Gilead Sciences USD 6.8B 1.29B Jun/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026